Latest / The So What? / A Story of African Innovation
Transcript
- 0:05Hello, and welcome to the So What podcast, in
- 0:08which political economic analyst J .P. Landman
- 0:11discusses the issues uppermost in the minds of
- 0:13South Africans. You can find a written version
- 0:16of this content on J .P.'s website, jplandman
- 0:19.co .za. I am Ruda Landman, and I am your host.
- 0:27Hello and welcome to this edition of the So What
- 0:32podcast, which accompanies JP's newsletter dated
- 0:35the 4th of February 2026 and titled A Story of
- 0:40African Innovation. JP, this is a bit of a different
- 0:44format. It is more of a report than what you
- 0:48usually write. Yes, absolutely. It's basically
- 0:50the story of a young entrepreneur from Pretoria.
- 0:53But it is such a good story that I thought I
- 0:55wanted to share it with readers. But also, secondly,
- 0:59because sadly, no South African media that I've
- 1:02seen reported on this story, and I thought it
- 1:05would be a useful thing to share. Where did you
- 1:07come across it? I came across it in the South
- 1:09China Morning Post, which is one of the newspapers
- 1:11that I read every day. And they carried a report
- 1:14in December, just before Christmas, of a function
- 1:17in Kigali in Rwanda, the African Business Heroes
- 1:21function, where people from all over Africa...
- 1:26were selected for the most innovative business
- 1:29ideas. And a young, as I said, entrepreneur from
- 1:33Pretoria, Adrian Krier, got the third prize of
- 1:37$150 ,000, which is about 2 .1 million rand.
- 1:40How many entries and how did Adrian Krier do?
- 1:45There were 32 ,000 entries from all over Africa.
- 1:48This is the seventh year. that the African Business
- 1:51Heroes competition is run. It is run by the Jack
- 1:55Ma Foundation and Alibaba Philanthropy. Now,
- 1:58readers will know that Jack Ma is the former
- 2:01schoolteacher who started the internet giant
- 2:04company Alibaba, now one of the biggest internet
- 2:07companies in the world. And they organized this
- 2:10competition, the African Business Heroes competition.
- 2:14And as I've said, it's in its seventh year. You
- 2:17ask how many people entered, 32 ,000 from all
- 2:20over Africa. The competition is very, very stiff.
- 2:23And you go through various interviews and rounds.
- 2:28And in the end, for the people in the final rounds,
- 2:31they go down and they do a due diligence on the
- 2:33company, right down to whether your tax affairs
- 2:35in your country are in order. So it's really
- 2:38a tough competition. And Adrian Krier, as I've
- 2:42said, got the third prize, $150 ,000. about 2
- 2:47.1, 2 .2 million rand tax -free, which is a huge
- 2:51amount of money. For a small business, definitely.
- 2:55How did he, his company's called what? Nouveau
- 2:57Tech, huh? With a Q at the end. How did it start?
- 3:01What was the problem they wanted to solve? It's
- 3:03a very interesting story. They started in 2014,
- 3:0612 years ago. He was a software specialist at
- 3:10Oracle and he resigned from his job together
- 3:12with his close friend, Abraham van Wyk. who used
- 3:15to be a medical practitioner. They both resigned
- 3:18their jobs and they started this company, NovoTech.
- 3:21Now, to understand what the company does, we've
- 3:24got to stand back a little bit. A little bit
- 3:26of background is necessary. Africa carries about
- 3:2918 % of the world's population, but it has about
- 3:33roughly 25 % of the global disease burden. Yet
- 3:38it only attracts about 3 % of global clinical
- 3:41research funding. So 80 % of the population,
- 3:451 .8, 25 % of the disease burden, but only 3
- 3:50% of clinical trials. In other words, of every
- 3:5310 ,000 clinical trial projects that are run
- 3:56worldwide every year, only about 300 are run
- 3:59in Africa. Now, this is most regrettable from
- 4:02two points of view. The one is it's a small participation
- 4:05by Africa in global medicine and global clinical
- 4:08trials. But secondly, Africa has got the unique
- 4:11advantage of a very wide genetic diversity pool.
- 4:16If you test a medicine here and it works, the
- 4:20chances are very good that it will work all over
- 4:22the world. China, Western Europe, North America,
- 4:25India. On the other hand, if you test the medicine
- 4:28in Scandinavia, for example, you don't know how
- 4:31people in China or in Latin America will metabolize
- 4:35that medicine. And it's very different. Now,
- 4:39more and more international biomedical companies
- 4:43realize this and they want to test or they want
- 4:46to run clinical tests here in Africa. Now, in
- 4:50Europe and in North America, Clinical trials
- 4:53are conducted digitally. Everything is done on
- 4:55computer, not the internet. In Africa, virtually
- 4:58all of it is done manually on paper. And there
- 5:02are several problems. You can imagine the stack
- 5:05of forms that you have to fill in. You can imagine
- 5:08the errors that creep in. You can imagine the
- 5:11time that it takes. So if you can digitize clinical
- 5:14trials or the running of clinical trials in Africa
- 5:18and get the process up to the standard of North
- 5:21America or Western Europe, it's really a huge
- 5:24step forward. And that is where they saw the
- 5:27gap. Plus, linked to that, the fact that Your
- 5:31big software companies are all based in Europe
- 5:34and North America. They're not based in Africa.
- 5:36So they thought as two Africans that they can
- 5:40step into this void and turn it into a business
- 5:43opportunity. And that is exactly what happened.
- 5:46Is it difficult to get into this field? It seems
- 5:50that software companies are a dime a dozen. Absolutely.
- 5:53Yes, it is difficult because you can't just write
- 5:55an app. to test medicine or to run a clinical
- 5:58trial. You have to meet the standards of the
- 6:00United States Federal Drug Administration and
- 6:03the European Medicines Council. They've got onerous
- 6:07standards and you've got to meet those standards.
- 6:09So the medical field is, what's the word, sui
- 6:12generis. It's something on its own. Something
- 6:14on its own, highly, highly regulated. And there
- 6:18is no room for mistakes, obviously, because it
- 6:20affects people's lives. In addition to that,
- 6:24what you find with the big pharmaceutical companies,
- 6:26they're very risk -averse. So they'll much rather
- 6:28run a trial in Canada or in Scandinavia than
- 6:32what they run it in Africa. Now, what the Novatec
- 6:35platforms do is they digitize the trial processes
- 6:39from end to end. And that is data capture of
- 6:42the people who are tested, validation, audit
- 6:45trails, compliance, and advanced analytics afterwards.
- 6:50It's clinical research today. It's clinical software.
- 6:54Processes are being used by universities, hospitals,
- 6:58research organizations, and pharmaceutical companies
- 7:01worldwide. Well, it seems to me that trust is
- 7:04the key. How did they build that? Absolutely.
- 7:07As Adrian Krieger himself says, you know, nobody
- 7:10would trust software that comes from two young
- 7:13guys in Pretoria. So they had to work hard at
- 7:17it. They started off with the help of an old
- 7:19university professor of his, Professor Koppel,
- 7:21who encouraged them and got them started on the
- 7:24road. But he admits that in the beginning they
- 7:27made many mistakes. They took shortcuts. They
- 7:30hired too cheaply. The software they developed
- 7:34was not good enough. And they had to rethink
- 7:38their game plan. which they did. They raised
- 7:42the rebuild properly. They raised money internationally
- 7:44from respected figures in global clinical research.
- 7:48They hired top -tier talent. What does top -tier
- 7:51talent mean? It means software engineers, medical
- 7:54doctors, statisticians, actuaries, and PhDs.
- 7:57Today they employ 70 highly qualified people
- 8:00all over the world, 35 in Gauteng, 10 in Cape
- 8:04Town, and the rest spread out in India, Brazil,
- 8:07Europe, and Kenya. So it's a big operation. And
- 8:11as Kriya says, the biggest factor that let him
- 8:15lie awake at night is that every month he's got
- 8:18to pay these highly qualified people 60 of them
- 8:20salaries. So the more than 2 million Rand prize
- 8:23money will come in very handy. Was there a breakthrough
- 8:27moment for them? Indeed, the breakthrough moment
- 8:30came with COVID -19. And what happened was a
- 8:34company from India. that they were in partnership
- 8:37with, contacted them and selected them, Nuvotec
- 8:40and Pretoria, to run a global clinical trial
- 8:44for COVID medicine. The trial was run across
- 8:47more than 50 hospitals and thousands of patients.
- 8:51And those results were tested and retested by
- 8:54the big pharmaceutical companies and the drug
- 8:57administration authorities. The global regulators.
- 9:00The global regulators. They went through the
- 9:02results with a fine tooth comb and accepted them.
- 9:05And that was the moment of breakthrough. That
- 9:07gave the trust, that gave the credibility. And
- 9:10the footprint today? Well, the footprint today
- 9:13is, as I've said, universities, research organizations
- 9:16worldwide use them, pharmaceutical companies
- 9:20use them, and they're the only company from Africa
- 9:22whose processes and products complies fully with
- 9:26the international regulators, specifically North
- 9:29American and European regulators. To go back
- 9:32to what you said in the beginning, what is the
- 9:34impact of this lack of digitization, apart from
- 9:39being a hindrance in finding research funding?
- 9:42But what does it mean in Africa? What it means
- 9:45in Africa is that patients still pay top prices
- 9:49for drugs, medicines, which are patented, while
- 9:53cheaper genetics are available. But the genetics
- 9:57have not been registered by the different authorities.
- 10:00So you pay five rand for a diabetes pill that
- 10:03could cost 50 cents. That is the biggest single
- 10:07problem in Africa. Why? Because the registration
- 10:10process is too cumbersome? Absolutely. It's cumbersome.
- 10:14Remember what I said, it's all paper -based.
- 10:17So it's a difficult process. For example, it
- 10:20takes the South African health products regulator
- 10:23about two months to work through one application
- 10:26for registration. It's a pack of documents that
- 10:30has to be submitted to the regulator and they
- 10:33have to go through it. They can't just skip the
- 10:35pages. And it takes about two months. So there
- 10:39are about 50 ,000 applications for generic medicines
- 10:44sitting with various regulators across the African
- 10:47continent. If you can clear that 50 ,000 backlog,
- 10:51it means it's 50 ,000 medicines or drugs which
- 10:55overnight will become much, much cheaper. And
- 10:58that will have a huge impact on health in Africa.
- 11:02So what can NovoTech and their processes do about
- 11:07this? How can they affect it? Yes, what NovoTech
- 11:10did is they created a not -for -profit division
- 11:12called the NovoTech Foundation. And they interact
- 11:16with these various regulators across Africa,
- 11:19also with the South African one, and they try
- 11:22and help them to digitize their processes. The
- 11:25funding for that comes from international philanthropy,
- 11:27like the Gates Foundation for one, and the other
- 11:30one is the European and Developing Countries
- 11:34Clinical Trials Partnership, EDCTP, a long, long
- 11:38name. In any case, they pay NovoTech Foundation.
- 11:42to conduct the research, conduct the development
- 11:44of programs. And they are being remunerated by
- 11:48these international philanthropy organizations.
- 11:51Now, in the case of South Africa, with the South
- 11:53African Health Products Regulatory Authority,
- 11:56it's the same story. They still follow very inefficient
- 12:01paper -based processes. So NovoTech is working
- 12:05with them. And through one of their subsidiaries
- 12:07called Sygenic, NovoTech has developed... using
- 12:11a team of data scientists and pharmacologists,
- 12:14they are building a solution for the South African
- 12:17Authority. What is the solution? Well, they took
- 12:20a large language model from Meta in the US, but
- 12:23based it in South Africa, in South African service,
- 12:26so that the information, the data, doesn't leave
- 12:28the continent. and make sure it's secured and
- 12:31based here. Because the cloud is not really in
- 12:34the cloud. It is actually somewhere on the servers.
- 12:37Exactly. So they hope to go alive with the Health
- 12:42Products Authority in South Africa within the
- 12:44course of 2026. Adrian is talking within a couple
- 12:48of months. What will that do to the registration
- 12:51of medicines? It will cut the processing time
- 12:54from, as I said earlier, about two months down
- 12:57to 45 minutes. It's an extraordinary solution.
- 13:01Now, those of you who've worked with AI will
- 13:04know this is precisely how it goes. You can take
- 13:06a long document of 50, 60 pages, and it gets
- 13:10summarized for you by AI. Better by some than
- 13:13by others, but it's being done. So that's what
- 13:15they're aiming for in South Africa in 2026. That'll
- 13:19make a huge difference to unlock the registration
- 13:22of medicines here in South Africa. What fascinates
- 13:25me about this is that so many of those documents
- 13:27are handwritten. Very true. So what they had
- 13:31to do, they had to train this large language
- 13:33model, not just to read all the documents and
- 13:36so on, but also to read handwriting. And it is
- 13:39still a bit of a mystery to me how they do that,
- 13:41because if you look at most doctors' handwriting.
- 13:45It is illegible even for a human. It is illegible
- 13:47even for a human. So how they taught the LLM
- 13:51to read that, I don't know, but they have. And
- 13:55yeah, as I said, they hope to go live later this
- 13:58year. In summary, so what? The first so what
- 14:01is Kruger's vision is very, very simple. Clinical
- 14:04research is $100 billion a year industry. And
- 14:08Africa only received about 3 % of that, $3 billion.
- 14:12If one can increase that share from 3 % to 5%,
- 14:16it will make a huge difference to healthcare,
- 14:19health infrastructure, and health professions
- 14:22here in Africa. That's the first so what. The
- 14:25second so what is clinical trials are very interesting
- 14:28in the sense that once the trial is over, it
- 14:31leaves behind it a sophisticated infrastructure,
- 14:35computer systems, knowledge, and so on. And you
- 14:38train people. You train people in the process
- 14:40of running the trial. That remains behind. So
- 14:44it's not just a question of doing the trial.
- 14:46You do it, but there's a footprint that is left
- 14:49behind on which you can build. The third one
- 14:52is I really cannot do better than just to quote
- 14:54Adrian Creer himself. He says, standing next
- 14:58to Jack Ma on stage in Rwanda was one of the
- 15:01most profound moments of my life, not because
- 15:04of the spotlight, but because it validated something
- 15:07we believed in for years. Africa doesn't need
- 15:10charity. It needs systems that works, and we're
- 15:14building them. On that very uplifting note, thank
- 15:18you very much, and good luck to Adrian and his
- 15:21team. Indeed. Thank you for listening to the
- 15:26So What Podcast. If you enjoy this content, please
- 15:29don't forget to leave a review and a rating,
- 15:32and please consider subscribing so you don't
- 15:34miss any future episodes. Also, tell your friends.
- 15:38Remember, you can find a written version of all
- 15:40JP's content at jplandman .co .za.